Skip to Content
Merck
CN

SML3042

iP300

≥97% (HPLC)

Synonym(s):

2-(3′-Fluoro-5′-(1-(2-(methylamino)-2-oxoethyl)-1H-pyrazol-4-yl)-2,5-dioxo-2′,3′-dihydrospiro[imidazolidine-4,1′-indene]-1-yl)-N-(4-fluorobenzyl)-N-(1,1,1-trifluoropropan-2-yl)acetamide, 3-Fluoro-N-[(4-fluorophenyl)methyl]-2,3-dihydro-5-[1-[2-(methylamino)-2-oxoethyl]-1H-pyrazol-4-yl]-2,5-dioxo-N-(2,2,2-trifluoro-1-methylethyl)spiro[imidazolidine-4,1-[1H]indene]-1-acetamide, N-(4-fluorobenzyl)-2-(3-fluoro-5-{1-[2-(methylamino)-2-oxoethyl]-1H-pyrazol-4-yl}-2,5-dioxo-2,3-dihydro-1H-spiro[imidazolidine-4,1-inden]-1-yl)-N-(1,1,1-trifluoropropan-2-yl)acetamide, iP300v/w, iP300w and iP300v mix, iP300w/v

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C29H27F5N6O4
CAS Number:
2624336-90-7
Molecular Weight:
618.55
UNSPSC Code:
12352200
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C29H27F5N6O4/c1-16(29(32,33)34)39(12-17-3-6-20(30)7-4-17)25(42)15-40-26(43)28(37-27(40)44)10-23(31)21-9-18(5-8-22(21)28)19-11-36-38(13-19)14-24(41)35-2/h3-9,11,13,16,23H,10,12,14-15H2,1-2H3,(H,35,41)(H,37,44)

InChI key

SWXCHCQCWFXILM-UHFFFAOYSA-N

SMILES string

O=C(NC1(C2=O)CC(C3=C1C=CC(C4=CN(N=C4)CC(NC)=O)=C3)F)N2CC(N(CC5=CC=C(C=C5)F)C(C(F)(F)F)C)=O

assay

≥97% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

Quality Level

100

Biochem/physiol Actions

Potent histone acetyltransferase p300/CBP inhibitor that prevents DUX4-induced cytotoxicity and transcription activity in vitro and in vivo.
iP300, a mixture of 8 diastereomers, is a potent histone acetyltransferase (HAT) p300/CBP inhibitor (p300 IC50 = 33 nM by H3K9Ac HTRF assay). An active diastereomer(s)-enriched pool (iP300w) obtained by partial HPLC separation prevents DUX4-induced cytotoxicity and transcription activity in human myoblast LHCN-M2 cultures (0.1-1 μM) and shows in vivo efficacy against muscle loss (0.3 mg/kg/day i.p.) in a murine model of facioscapulohumeral muscular dystrophy (FSHD).

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Darko Bosnakovski et al.
Science advances, 5(9), eaaw7781-eaaw7781 (2019-09-20)
Facioscapulohumeral muscular dystrophy (FSHD) results from mutations causing overexpression of the transcription factor, DUX4, which interacts with the histone acetyltransferases, EP300 and CBP. We describe the activity of a new spirocyclic EP300/CBP inhibitor, iP300w, which inhibits the cytotoxicity of the

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service